Your browser doesn't support javascript.
Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation.
Climente-Martí, Mónica; Ruiz-Millo, Oreto; López-Cruz, Ian; Atienza-García, Ángel; Martínez-Moragón, Eva; Garijo-Gómez, Emilio; López-Grima, María Luisa; Zaragoza-Crespo, Rafael; Llau-Pitarch, Juan Vicente; Bautista-Rentero, Daniel; Nogueira-Coito, José Miguel; Ripollés-González, Tomás; Marco-Artal, María Antonia; Romero-Serrano, Ramón; Dolz-Sinisterra, Francisco; López-Estudillo, Rosario.
  • Climente-Martí M; Pharmacy Department, Doctor Peset University Hospital, Valencia, Spain.
  • Ruiz-Millo O; Pharmacy Department, Doctor Peset University Hospital, Valencia, Spain.
  • López-Cruz I; Internal Medicine Department, Doctor Peset University Hospital, Valencia, Spain.
  • Atienza-García Á; Internal Medicine Department, Doctor Peset University Hospital, Valencia, Spain.
  • Martínez-Moragón E; Pneumologia Department, Doctor Peset University Hospital, Valencia, Spain.
  • Garijo-Gómez E; Short Stay Unit, Doctor Peset University Hospital, Valencia, Spain.
  • López-Grima ML; Emergency Department, Doctor Peset University Hospital, Valencia, Spain.
  • Zaragoza-Crespo R; Critical Care Department, Doctor Peset University Hospital, Valencia, Spain.
  • Llau-Pitarch JV; Anaesthesiology and Postsurgical Critical Care Department, Doctor Peset University Hospital, Valencia, Spain.
  • Bautista-Rentero D; Preventive Medicine Department, Doctor Peset University Hospital, Valencia, Spain.
  • Nogueira-Coito JM; Clinical Microbiology Department, Doctor Peset University Hospital, Valencia, Spain.
  • Ripollés-González T; Radiology Department, Doctor Peset University Hospital, Valencia, Spain.
  • Marco-Artal MA; Occupational Risk Prevention Department, Doctor Peset University Hospital, Valencia, Spain.
  • Romero-Serrano R; Health Information Management Department, Doctor Peset University Hospital, Valencia, Spain.
  • Dolz-Sinisterra F; Chief Executive Officer, Doctor Peset University Hospital, Valencia, Spain.
  • López-Estudillo R; Medical Director, Doctor Peset University Hospital, Valencia, Spain.
Int J Clin Pract ; 75(9): e14479, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1262333
ABSTRACT

INTRODUCTION:

In addition to respiratory support needs, patients' characteristics to guide indication or timing of corticosteroid treatment in COVID-19 patients are not completely established. This study aimed to evaluate the impact of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation (PI-SSI).

METHODS:

Between 9 March and 5 May 2020 (final follow-up on 2 July 2020), a retrospective cohort study was conducted in hospitalised patients with COVID-19 PI-SSI (≥2 inflammatory biomarkers [IBs] temperature ≥38℃, lymphocyte ≤800 cell/µL, C-reactive protein ≥100 mg/L, lactate dehydrogenase ≥300 units/L, ferritin ≥1000 mcg/L, D-dimer ≥500 ng/mL). Patients received 0.5-1.0 mg/kg of methylprednisolone for 5-10 days or standard of care. The primary outcome was 28-day all-cause mortality. Secondary outcomes included ≥2 points improvement on a 7-item WHO-scale (Day 14), transfer to intensive care unit (ICU) (Day 28) and adverse effects. Kaplan-Meier method and Cox proportional hazard regression were implemented to analyse the time to event outcomes.

RESULTS:

A total of 142 patients (corticosteroid group n = 72, control group n = 70) were included. A significant reduction in 28-day all-cause mortality was shown with methylprednisolone in patients with respiratory support (HR 0.15; 95% CI 0.03-0.71), with ≥3 (HR 0.17; 95% CI 0.05-0.61) or ≥4 altered IB (HR 0.15; 95% CI 0.04-0.54) and in patients with both respiratory support and ≥3 (HR 0.11; 95% CI 0.02-0.53] or ≥4 altered IB (HR 0.14; 95% CI 0.04-0.51). No significant differences were found in secondary outcomes.

CONCLUSION:

Intermediate to high doses of methylprednisolone, initiated between 5 and 12 days after symptom onset, was associated with a significant reduction in 28-day all-cause mortality in patients with COVID-19 pneumonia and ≥3 o ≥ 4 altered IB, independently of the need of respiratory support.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Methylprednisolone / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Int J Clin Pract Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Ijcp.14479

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Methylprednisolone / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Int J Clin Pract Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Ijcp.14479